Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Peptidomimetics as a new strategy to modulate Aurora-A and combat cancer

A new approach to targeting a protein involved in cell division, which can misfunction in cancer, has revealed new insights into how it functions.

3 Dec 2024

UQ researchers move closer to developing topical cream for skin cancers in transplant patients

A topical cream to help prevent and treat skin cancers in organ transplant patients is a step closer to development.

28 Nov 2024

A roadmap for understanding antimalarial drug resistance

Researchers at University of California San Diego analyzed the genomes of hundreds of malaria parasites to determine which genetic variants are most likely to confer drug resistance.

28 Nov 2024

Research shows "Alzheimer's in a dish" model can accelerate drug discovery

A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the model uses cultures of mature brain cells suspended in a gel to recapitulate what takes place in the human brain over 10 to 13 years in just six weeks.

27 Nov 2024

Cardiovascular disease risk linked to early brain decline in men

Men with cardiovascular disease risk factors, including obesity, face brain health decline a decade earlier - from their mid 50s to mid 70s - than similarly affected women who are most susceptible from their mid 60s to mid 70s, suggest the findings of a long term study, published online in the Journal of Neurology Neurosurgery & Psychiatry.

26 Nov 2024

Metrion Biosciences appoints Lee Patterson as CEO

Metrion Biosciences (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets.

From Metrion Biosciences Limited 26 Nov 2024

Atlas maps plasma proteins to transform disease diagnosis and treatment

Researchers have developed the most comprehensive atlas linking plasma proteins to diseases and traits in over 53,000 individuals, offering groundbreaking insights for precision medicine. This resource uncovers 168,100 protein-disease associations and identifies new therapeutic targets.

25 Nov 2024

USC and Autobahn Labs team up to advance breakthrough drug research

USC has embarked on a collaboration with Autobahn Labs, an accelerator for early-stage drug discovery, to identify and advance cutting-edge scientific findings into new therapies - with a special focus on critical unmet medical needs.

22 Nov 2024

AI-designed drug ISM5939 granted IND clearance for cancer clinical trials

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors.

22 Nov 2024

Advanced diagnostic kit developed for detecting highly pathogenic H5N1 avian influenza virus

The Diagnostics Development Hub (DxD Hub), a national platform hosted by the Agency for Science, Technology and Research (A*STAR), Singapore, in collaboration with the National Institute for Environmental Studies (NIES), Japan, and the A*STAR Bioinformatics Institute (A*STAR BII), has successfully developed Steadfast, an advanced diagnostic kit for detecting the highly pathogenic H5N1 Avian Influenza Virus (AIV).

22 Nov 2024

Natural fat molecule shows promise for treating diabetic heart disease

Monash University drug discovery researchers have found that a natural fat molecule called ‘lipoxin A4’ (LXA4) could significantly reduce inflammation and improve function for diabetic hearts.

21 Nov 2024

First 'blueprint' of human skeletal development offers new insights into bone formation

The first 'blueprint' of human skeletal development reveals how the skeleton forms, shedding light on the process of arthritis, and highlighting cells involved in conditions that affect skull and bone growth.

21 Nov 2024

Modified darobactin offers hope for combatting antibiotic-resistant bacteria

Antibacterial drugs are important for treating infections. But increasingly, bacterial resistance to current drugs - so they don't work well, or even at all - means new ones are urgently needed.

21 Nov 2024

New atlas maps 1.6 million human gut cells in unprecedented detail

The most comprehensive cell map of the human gut to date has been created by combining spatial and single-cell data from 1.6 million cells.

21 Nov 2024

New approach to stabilize RSV protein could lead to better vaccines

In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can cause severe pneumonia and even death.

20 Nov 2024

From crude lysate to purity with high-precision AAV capsid measurement with Bio-Rad's new ddPCR Kit

Accurately quantify AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit—offering reliable, efficient, and precise measurement to streamline your research workflows.

From Bio-Rad Laboratories 19 Nov 2024

Small Solutions for Big Problems in Drug Discovery and Delivery

Ijeoma Uchegbu discusses nanomedicine's role in improving medication adherence and developing non-addictive pain relief solutions at ELRIG Drug Discovery 2024.

19 Nov 2024

Largest ALS patient-based iPSC repository opens new frontiers in research

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem cell (iPSC) and bio data repository.

15 Nov 2024

Argonne receives $21.7 million to advance cancer and vaccine discoveries

The U.S. Department of Energy's (DOE) Argonne National Laboratory will use its world-leading capabilities in artificial intelligence (AI) and high performance computing to research novel ways to fight cancer and transform vaccine discovery.

15 Nov 2024

CN Bio launches PhysioMimix Bioavailability assay kit: Human 18

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.

14 Nov 2024